Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-12-11
2007-12-11
Yaen, Christopher H. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
10376286
ABSTRACT:
The invention is directed to diagnostic and monitoring methods (assays) for cancer and kits that may be used in such methods. More particularly, an aspect of the invention relates to the use of activated Stat5 for diagnosing and monitoring breast cancer and predicting the effectiveness of cancer treatment. The invention also relates to the use of screening assays for discovering compounds that effect levels of activated Stat5.
REFERENCES:
patent: 5244787 (1993-09-01), Key et al.
patent: 5578452 (1996-11-01), Shi et al.
patent: 5599681 (1997-02-01), Epstein et al.
patent: 5707803 (1998-01-01), Lamb et al.
patent: 6306653 (2001-10-01), Papsidero et al.
patent: 0 217 577 (1987-04-01), None
patent: WO 83/03679 (1983-10-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 00/44774 (2000-08-01), None
Waston et al. Br. J. Cancer, 1995, 71(4): 840-4.
Ho et al., blood, 1999, 93(12): 4354-4364.
Turkson et al., Oncogene 2000, 19:6613-6626.
Bowman et al., Oncogene 2000, 19: 2474-2488.
Bradshaw et al., Adv. Protein chem. 2002, 61: 161-210.
Nishimura et al., Mol. Cell. Biol., 1993, 13(11): 6889-6896.
Barber et al., Blood, 2001, 97(8): 2230-2237.
Reich et al., Nature Reviews, Immunology, 2006, 6: 602-612.
Allred, D.C. et al., “Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis,”Mod. Pathol. 11:155-168, The United States and Canadian Academy of Pathology, Inc. (1998).
Apantaku, L.M., “Breast Cancer Diagnosis and Screening ,”Am. Fam. Phnysician 62:596-602, 605-606, American Academy of Family Physicians (Aug. 2000).
Ariyoshi, K. et al., “Constitutive Activation of STAT5 by a Point Mutation in the SH2 Domain,”J. Biol. Chem. 275:24407-24413, The American Society for Biochemistry and Molecular Biology, Inc. (Aug. 2000).
Azam, M. et al., “Functionally Distinct Isoforms of STAT5 Are Generated by Protein Processing,”Immunity 6:691-701, Cell Press (1997).
Barahmand-Pour, F. et al., “Jak2-Stat5 Interactions Analyzed in Yeast,”J. Biol. Chem. 273:12567-12575, The American Society for Biochemistry and Molecular Biology, Inc. (1998).
Berg, K. et al., “Photochemical Internalization: A Novel Technology for Delivery of Macromolecules into Cytosol,”Cancer Res. 59:1180-1183, Amercan Association for Cancer Research (1999).
Berois, N. et al., “Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR,”Eur. J. Cancer 36:717-723, Elsevier Science Ltd. (Apr. 2000).
Bishayee, A. et al., “Phosphorylation of Tyrosine 992, 1068 and 1086 Is Required for Conformational Change of the Human Epidermal Growth Factor Receptor C-Terminal Tail,”Mol. Biol. Cell 10:525-536, The American Society for Cell Biology (Mar. 1999).
Boon, M.E. and Kok, L.P., “Microwaves for immunohistochemistry,”Micron 25:151-170, Elsevier Science Ltd. (1994).
Braun, S. et al., “Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with State I, II or III Breast Cancer,”N. Engl. J. Med. 342:525-533, The Massachnusetts Medical Society (Feb. 2000).
Bridges. R.S., “The role of lactogenic hormones in maternal behavior in female rats,”Acta Paediatr. Suppl. 397:33-39, Scandinavian University Press (1994).
Bromberg, J. and Darnell Jr., J.E., “The role of STATs in transcriptional control and their impact on cellular function,”Oncogene 19:2468-2473, Macmillan Publishers Ltd. (May 2000).
Brown, C., “Antigen Retrieval Methods for Immunohistochemistry,”Toxicol Pathol. 26:830-831, Society of Toxicologic Pathologist (1998).
Cardosi, R.J. and Fiorica, J.V., “Surveillance of the endometrium in tamoxifen treated women,”Curr. Opin. Obstet. Gynecol. 12:27-31, Lippincott Williams & Wilkins (Feb. 2000).
Chen, J. et al., “Stat5 is a physiological substrate of the insulin receptor,”Proc. Natl. Acad. Sci. USA 94:2295-2300, The National Academy of Sciences of the USA (1997).
Cochrane, D. et al., “Identification of Natural Ligand for SH2 Domains from a Phage Display cDNA Library,”J. Mol. Biol. 297:89-97, Academic Press (Mar. 2000).
Cole, P., “Major Aspects of the Epidemiology of Breast Cancer,”Cancer 46:865-867, American Cancer Society (1980).
Cristiano, R.J., “Targeted, Non-Viral Gene Delivery for Cancer Gene Therapy,”Front. Biosci. 3:D1161-D1170, Frontiers in Bioscience, Inc. (1998).
Dahiya, R. and Deng. G., “Molecular prognostic markers in breast cancer,”Breast Cancer Res. Treat. 52:185-200, Kluwer Academic Publishers (1998).
Darnell Jr., J.E., “STATs and gene regulation,”Science 277:1630-1635, The American Association for the Advancement of Science (1997).
Darnell Jr., J.E., “Studies of IFN-Induced Transcriptional Activation Uncover the Jak-Stat Pathway,”J. Interferon Cytokine Res. 18:549-554, The Rockefeller University Press (1998).
Del Mastro, L. and Venturini, M., “Strategies for the Use of Epoetin Alfa in Breast Cancer Patients,”Oncologist 3:314-318, AlphaMed press (1998).
Dente, L. et al., “Modified Phage Peptide Libraries as a Tool to Study Specificity of Phosphorylation and Recognition of Tyrosine Containing Peptides,”J. Mol. Biol. 269:694-703, Academic Press Limited (1997).
Doi, N. and Yanagawa, H., “Screening of conformationally constrained random polypeptide libraries displayed on a protein scaffold,”Cell Mol. Life Sci. 54:394-404, Birkhäuser Verlag (1998).
Doi, N. and Yanagawa, H., “STABLE: protein-DNA fusion system for screening of combinatiorial protein libraries in vitro,”FEBS Lett. 457:227-230, Federation of European Biochemical Societies (1999).
Elledge, R.M. and McGuire, W.L., “Prognostic and Therapeutic Decisions in Axillary Node-Negative Breast Cancer,”Annu. Rev. Med. 44:201-210, Annual Reviews, Inc. (1993).
Fata, J.E., et al., “The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development,”Cell 103:41-50, Cell Press (Sep. 2000).
Fetsch, P.A. et al., “Detection of Circulating Tumor Cells and Micrometastases in Stage II, III and IV Breast Cancer Patients Utilizing Cytology and Immunocytochemistry,”Diagn. Cytopathol. 22:323-328, Wiley-Liss, Inc. (May 2000).
Fitzgibbons, P.L. et al., “Prognostic Factors in Breast Cancer. College of American Pathologists Consensus Statement 1999,”Arch. Pathol. Lab. Med. 124:966-978, College of American Pathologists (Jul. 2000).
Freije, J.M. et al.. “Nm23 and tumour metastasis: basic and translational advances,”Biochem. Soc. Symp. 63:261-271, Portland Press (1998).
Fresno, M. et al., “p53 Expression is of Independent Predictive Value in Lymph Node-Negative Breast Carcinoma,”Eur. J. Cancer 33:1268-1274, Elsevier Science Ltd. (1997).
Gail, M.H. et al., “Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer,”J. Natl. Cancer Inst. 91:1829-1846, Oxford University Press (1999).
Glockshuber, R. et al., “A Comparision of Strategies to Stabilize Immunoglulin Fv-Fragments,”Biochemistry 29:1362-1367, American Chemical Society (1990).
Gouilleux, F. et al., “Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription,”EMBO J. 13:4361-4369, Oxford University Press (1994).
Gram, H. et al., “Identification of phosphopeptide ligands for the Src-homology 2 (SH2) domain of Grb2 by phage display,”Eur. J. Biochem. 246:633-637, Federation of European Biochemical Societies (1997).
Gram, H., “Phage Display in Proteolysis and Signal Transduction,”Comb. Chem. High Throughput Screen 2:19-28, Bentham Science Publishers B.V. (1999).
Grimley, P.M. et al., “Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation,”Cytokine Gr
Nevalainen Marja T.
Rui Hallgeir
Conley & Rose, P.C.
Sang Hong
Yaen Christopher H.
LandOfFree
Diagnostic and monitoring methods for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic and monitoring methods for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic and monitoring methods for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862098